NHS

England

Product specification: Rituximab 250ml & 500ml infusion bags

	Name of product	Rituximab infusion. Aseptically prepared from licensed sterile starting materials.
	Concentration	Concentration range 1mg/ml to 4mg/ml in infusion bags in accordance with the national dose banding tables. The Rituximab concentrate should be added to the bag without withdrawal of equivalent volume of Sodium Chloride 0.9% w/v Infusion unless withdrawal of some infusion fluid is required to accomodate the total dose.
	Diluent	Sodium Chloride 0.9% w/v
	Volume	400mg to 550mg in 250ml (290ml to 300ml including addition volume) 600mg to 1200mg in 500ml (560ml to 600ml including addition volume)
	Final container	Non-PVC e.g. polyolefin infusion bag with additive port cover. *Ideally infusion bag design will incorporate self sealing giving port to minimise H&S risks associated with accidental spillage during administration.*
	Starting materials	Licensed Rituximab 10mg/ml (MabThera® or Biosimilar) concentrate solution for infusion. Licensed Sodium Chloride 0.9% w/v Infusion bags
	Labelling	Labelling must be compliant with the principles of labelling for safety and the BP General specification on unlicensed medicines.Tall Man lettering must be used for the drug name. NB: The brand name e.g. brand leader or subsequent biosimilars must be included on the label.
	Label sample	An example label is provided below stating the minimum requirements only (the label format is not restrictive and suppliers can use their preferred layout):- RITUXimab (Brand Name) xxxmg in xxxml Sodium chloride 0.9% w/v For Intravenous Infusion Infuse the entire contents of the bag Store in a Refrigerator at 2-8°C Protect From Light Expiry: dd/mm/yyyy BN: XXXXXXXXX Keep out of the reach and sight of children Manufacturer's details MS XXXXXX
	Batch Number	All products will have a unique batch identification number
	Latex status of - components - manufacturing process	All materials and manufacturing processes will be latex free or clearly labelled if not.
	Stability	The stability study should conform to the Standard Protocol for deriving and assessment of stability of Aseptic preparations (Biopharmaceuticals) published by the NHS Pharmaceutical QA Committee (3rd Edition, April 2017).